Tweet
Originally posted by AllSeq
View Post
-
Brilliant move or sign of desperation on the part of Roche? After sending $60M+ down the drain with IBM they are now back to the big dance, now with (apparently) murky IP situation. ONT has licensed so much IP on the biochemistry side that it is not clear (to me) how Genia works around that. Judging from the patents that are now published, the sensors themselves are interesting but not terribly unique. The guys know their analog design (duh), but without biochemistry they will go nowhere. Maybe this is what Roche is banking on - take the platform and add their own biochemistry. -
Genia seems to be claiming two advantages:Originally posted by BBoy View Post
1) Precise control over the nanopore assembly process, allowing for 'better than Poisson' distribution
2) NanoTag biochemistry (being co-developed with Columbia and Harvard)
Do you not think this biochemistry confers an advantage (or are you saying they don't really 'own' it due to the murky nanopore IP situation)?Comment
-
Their hardware, as much as can be judged from their patents and public presentations is elegant. Murky biochem IP is indeed the right way to characterize things. There are multiple startups, universities, and established companies working in this area, some with overlapping IP claims. It will be interesting to sit back and watch the lawyers get paid large amounts of money to argue about trivialities.Originally posted by AllSeq View PostComment
-
I'm curious about this part as well. I wonder if Thermo Fisher dumped any ties with Genia after the Life acquisition?Originally posted by scbaker View PostComment
-
Still haven't heard anything else about the group working on Starlight.Originally posted by snetmcom View Post
As for Thermo, my assumption is they still own a portion Genia and will make a bit of money on their investment once the acquisition closes.Comment
-
Data variability is still an issue in sequencing technologies despite the advances in reproducibility and accuracy of these platforms. But the problem does not originate in the sequencing itself, but in the previous steps, before the sample reaches the sequencer.
The first step is collection, followed by preservation and sample preparation for analysis. Most scientists overlook those steps, but not being careful might just be skewing the experiment’s results.
...06-02-2026, 10:05 AM -
With the launch of new single-cell sequencing platforms in 2026, the field stands at an exciting inflection point. This article surveys the most impactful advances in the field and discusses how they’re reshaping research in cancer, immunology, and beyond.
Introduction
Single-cell sequencing technologies have undergone remarkable advances over the past decade, transitioning from low-throughput experimental approaches to highly scalable platforms capable of...05-22-2026, 06:42 AM
Comment